Linzolid Injection 2 mg/ml is a powerful intravenous antibiotic from the oxazolidinone class, designed to treat serious infections caused by Gram-positive bacteria, including multidrug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). This formulation is ideal for patients who are unable to take oral medications or require rapid therapeutic plasma levels for severe infections.

Linezolid, the active ingredient, inhibits bacterial protein synthesis, preventing growth and proliferation of susceptible organisms. Its broad spectrum of activity and excellent tissue penetration make it a preferred choice for hospital-acquired infections, complicated skin and soft tissue infections, and severe pneumonia.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Oxazolidinone antibiotics

• Anti-Gram-positive bacterial agent

Pharmacology

Linezolid is a bacteriostatic antibiotic that targets the 50S subunit of bacterial ribosomes, specifically binding to the 23S rRNA. This prevents formation of the initiation complex required for protein synthesis, effectively halting bacterial growth.

Pharmacokinetics:

• Absorption: As an intravenous formulation, Linzolid injection ensures 100% bioavailability, bypassing gastrointestinal absorption limitations.

• Distribution: Rapidly distributes into lung tissue, skin, and soft tissues, achieving therapeutic concentrations at infection sites.

• Metabolism: Metabolized primarily via non-enzymatic oxidation in the liver into inactive metabolites.

• Excretion: Approximately 30–40% excreted unchanged in urine; remainder as metabolites.

• Half-life: 4.5–5.5 hours, supporting twice-daily dosing.

Indications

Linzolid Injection 2 mg/ml is indicated for:

• Complicated and uncomplicated skin and soft tissue infections, including MRSA infections

• Nosocomial and community-acquired pneumonia caused by Gram-positive bacteria

• Severe infections caused by vancomycin-resistant Enterococcus (VRE)

• Other serious Gram-positive infections in patients requiring intravenous therapy

Dosage and Administration

• Adults: 600 mg IV every 12 hours, infused over 30–120 minutes

• Children: Dose based on body weight; use under strict medical supervision

• Duration: Typically 10–14 days, depending on infection severity and clinical response

• The solution should be inspected for particulate matter and discoloration before administration.

Contraindications

• Hypersensitivity to Linezolid or other oxazolidinones

• Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 2 weeks of MAOI therapy due to risk of serotonin syndrome

• Uncontrolled hypertension or patients taking serotonergic agents

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Common side effects include:

• Gastrointestinal: nausea, vomiting, diarrhea

• Hematologic: reversible thrombocytopenia, anemia, neutropenia (especially with prolonged therapy)

• Neurological: headache, dizziness, insomnia; peripheral neuropathy with long-term use

• Rare but serious: lactic acidosis, serotonin syndrome, optic neuropathy

Precautions and Warnings

• Monitor complete blood counts, especially for treatments longer than 2 weeks

• Use with caution in patients with renal or hepatic impairment

• Avoid foods high in tyramine and concurrent serotonergic drugs to prevent hypertensive crises or serotonin syndrome

• Adjust infusion rate in patients with cardiac conditions

Pregnancy and Lactation

• Use only if the potential benefit justifies the risk; limited safety data in pregnant women

• Linezolid is excreted in breast milk; breastfeeding should be discontinued during therapy

Storage Conditions

Store below 30°C in a dry, light-protected area. Do not freeze. Keep out of reach of children.